Axsome Therapeutics, Inc.
AXSM · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $638M | $386M | +65.5% |
| Operating income | −$167M | −$281M | +40.6% |
| Net income | −$183M | −$287M | +36.2% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 2, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $260M | $171M | +51.9% |
| Operating income | −$11.1M | −$46.1M | +75.9% |
| Net income | −$12.9M | −$47.2M | +72.7% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Axsome's revenue in FY2025?
- $638M in FY2025 (Fiscal year ended Dec 31, 2025), +65.5% vs $386M a year earlier, per its 10-K filed Feb 2026.
- Was Axsome profitable in FY2025?
- No: net income was −$183M and operating income −$167M in FY2025.
- What was Axsome's revenue in Q3 2026?
- $260M (+51.9% vs a year earlier), per its Form 10-Q filed Nov 2, 2026.